Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Citi
US Army
UBS
Queensland Health
Colorcon
Accenture
Moodys
Daiichi Sankyo

Generated: December 18, 2018

DrugPatentWatch Database Preview

SAMSCA Drug Profile

« Back to Dashboard

Which patents cover Samsca, and what generic alternatives are available?

Samsca is a drug marketed by Otsuka America Pharm and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has seventy-five patent family members in nineteen countries.

The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tolvaptan profile page.

Drug patent expirations by year for SAMSCA
Pharmacology for SAMSCA
Synonyms for SAMSCA
(-)-4'-((7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl)-o-tolu-m-toluidide
(+-)-4'-((7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl) carbonyl)-o-tolu-m-toluidide
(+-)-4'-((7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl)-o-tolu-m-toluidide
150683-30-0
4CA-1265
5-hydroxy-7-chloro-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1h-benzazepine
683T300
7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine
7-chloro-5-hydroxy-1-[2-methyl-4-(2-methyl benzoyl amino) benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine
7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino) benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine
7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine
AB0009995
AB01565822_02
AB2000685
AC-22748
AC1L50C9
AK-33401
AKOS015994735
AM20090726
AN-5238
ANW-59865
API0024498
AX8158397
BC650606
BDBM35723
Benzamide, N-(4-((7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl)-3-methylphenyl)-2-methyl-
Benzamide, N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methyl-
benzazepine derivative, 32
C26H25ClN2O3
CAS-150683-30-0
CHEBI:32246
CHEMBL344159
CS-0572
CT0200
CTK8B8272
D03KZM
DSSTox_CID_28706
DSSTox_GSID_48780
DSSTox_RID_82975
DTXSID3048780
FT-0645839
GTPL2226
GYHCTFXIZSNGJT-UHFFFAOYSA-N
HE140100
HMS3604L08
HMS3656K20
HSDB 8196
HY-17000
IN2270
jinarc
KB-61802
KS-1315
L001628
MFCD09837707
MolPort-008-155-996
N-(4-(7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-benzo[b]-azepine-1-carbonyl)-3-methylphenyl)-2-methylbenzamide
N-(4-(7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)-3-methylphenyl)-2-methylbenzamide
N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methyl-phenyl]-2-methyl-benzamide
N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide
N-[4-(7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-benzo[b]azepine-1-carbonyl)-3-methyl-phenyl]-2-methyl-benzamide
N-[4-(7-chloro-5-hydroxy2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide
N-[4-(9-chloro-6-hydroxy-2-azabicyclo[5.4.0]undeca-8,10,12-triene-2-carbonyl)-3-methyl-phenyl]-2-methyl-benzamide
N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide
NCGC00183001-01
OPC 41061
OPC-41061
PDSP1_001738
PDSP2_001721
s2593
Samsca (TN)
Samsca;OPC-41061
SCHEMBL242421
SR-01000942265
SR-01000942265-1
ST24031322
TC-148610
Tolvaptan
Tolvaptan (OPC-41061)
Tolvaptan [USAN:INN:BAN]
Tolvaptan, >=98% (HPLC), powder
Tox21_113256

US Patents and Regulatory Information for SAMSCA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-001 May 19, 2009 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-002 May 19, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-001 May 19, 2009 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-002 May 19, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-003 May 19, 2009 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for SAMSCA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-003 May 19, 2009 ➤ Sign Up ➤ Sign Up
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-001 May 19, 2009 ➤ Sign Up ➤ Sign Up
Otsuka America Pharm SAMSCA tolvaptan TABLET;ORAL 022275-002 May 19, 2009 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for SAMSCA
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 60 mg ➤ Subscribe ➤ Sign Up
➤ Subscribe Tablets 15 mg and 30 mg ➤ Subscribe ➤ Sign Up

Supplementary Protection Certificates for SAMSCA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0408 Netherlands ➤ Sign Up 300408, 20101018, EXPIRES: 20151017
C0049 France ➤ Sign Up PRODUCT NAME: TOLVAPTAN, EVENTUELLEMENT SOUS FORME DE SEL; REGISTRATION NO/DATE: EU/1/09/539/001 20090803
C/GB09/037 United Kingdom ➤ Sign Up PRODUCT NAME: TOLVAPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/09/539/001 20090803; UK EU/1/09/539/002 20090803; UK EU/1/09/539/003 20090803; UK EU/1/09/539/004 20090803
00408 Netherlands ➤ Sign Up PRODUCT NAME: TOLVAPTAN, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/09/539/001-004 20090803
2009 00031 Denmark ➤ Sign Up
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Citi
US Army
UBS
Queensland Health
Colorcon
Accenture
Moodys
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.